MRK Stock UPDATES Merck & Company (MRK) 58.78 08/14/2014 20:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck & Company (MRK) 58.78 $MRK

Pfizer's Prevnar 13 Backed by U.S. Panel for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:10PM CDT
Pfizer's (PFE) Prevnar 13 has been backed for regular use in patients aged 65 years and above.

Merck's Insomnia Drug Belsomra Approved by the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:00PM CDT
Merck (MRK) announced that the FDA has approved Belsomra.

Global Contraceptives Market 2014-2018: Key Vendors are Actavis, Bayer, Johnson & Johnson's, Janssen, Merck & Co, Pfizer and Teva
PR Newswire Europe - Thu Aug 14, 1:36PM CDT
DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/5kt24m/global] has announced the addition of the "Global Contraceptives Market 2014-2018" [http://www.researchandmarkets.com/research/5kt24m/global] report to their offering.

DrugDev Continues to Collaborate, Share Ideas and Innovate With Clinical Trial Leaders and Global Investigators at Key Upcoming Conferences This Fall
Business Wire - Thu Aug 14, 12:06PM CDT
DrugDev is committed to collaborating and sharing ideas with sponsors, CROs and sites to understand their challenges and to develop innovative technology-driven solutions that enable them to do more trials together. DrugDev executives and technologists will speak and participate at key industry conferences in September and October, including...

GTCR Announces Partnership With David Snow to Form Cedar Gate Technologies
Business Wire - Thu Aug 14, 10:27AM CDT
GTCR, a leading private equity firm, today announced that it has entered into a partnership with David Snow to form Cedar Gate Technologies, LLC ("Cedar Gate" . The new company, headquartered in Darien, Connecticut, will focus on acquiring companies and products in the healthcare information technology (HCIT) industry as part of a strategy to build a market leading healthcare data and analytics company. GTCR, the firm that pioneered the Leaders Strategy(TM) - finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth - plans to invest up to $200 million of equity capital to support the strategy. Mr. Snow will serve as the Chairman and Chief Executive Officer of Cedar Gate and plans to invest up to $20 million.

Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
PR Newswire - Thu Aug 14, 8:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and actress S. Epatha Merkerson are bringing the America's Diabetes Challenge: Get to Your Goals program to Dallas, Texas to encourage African Americans with type 2 diabetes to know their A1C--their average blood sugar level over the past two to three months--and talk to their doctors about setting and attaining a personal A1C goal. Merkerson, one of the 4.9 million African-American adults living with type 2 diabetes, will attend the American Diabetes Association's Live Empowered event in Dallas, Texas at Concord Church on August 14 to share her story.

Why Pfizer (PFE) Stock Is Up Today
at The Street - Thu Aug 14, 7:25AM CDT
The company won the backing of a key U.S. advisory panel to recommend its vaccine Prevnar 13 for people ages 65 and older to help prevent infections including pneumonia.

Global Sun Care Product Market 2014-2018: Key Vendors are Beiersdorf, Johnson & Johnson, L'Oreal and Merck
GlobeNewswire - Thu Aug 14, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p3rf75/global_sun_care) has announced the addition of the "Global Sun Care Product Market 2014-2018" report to their offering.

Must-See Charts: 5 Big Stocks to Trade for Gains
at The Street - Thu Aug 14, 6:00AM CDT
Here's how to trade some of the biggest stocks on Wall Street.

Merck wins US FDA's approval for BELSOMRA for the treatment of insomnia in adults
M2 - Thu Aug 14, 4:41AM CDT
Healthcare company Merck (NYSE:MRK) reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for BELSOMRA (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep.

Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - Thu Aug 14, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (8) - Europe (19) - France (1) - Germany (8) - The United Kingdom (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (24) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/bq...th_factors

Merck Statement regarding Role of PNEUMOVAX(R) 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults
Business Wire - Wed Aug 13, 4:58PM CDT
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices' (ACIP's) updated pneumococcal vaccine recommendations for adults 65 years of age and older. These recommendations call for a two vaccine regimen utilizing a dose of the pneumococcal conjugate vaccine followed by a dose of Merck's PNEUMOVAX(R) 23, at an interval to be determined by the ACIP, in adults 65 years of age and older who have not previously received pneumococcal vaccine. ACIP also voted that these recommendations for routine use of the pneumococcal conjugate vaccine in adults 65 years of age and older should be reevaluated in 2018 and revised as needed. ACIP will continue to monitor disease trends and the impact of these new recommendations.

FDA Approves BELSOMRA(R) (suvorexant) for the Treatment of Insomnia
Business Wire - Wed Aug 13, 3:49PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA(R) (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. The mechanism by which BELSOMRA exerts its therapeutic effect is presumed to be through antagonism of orexin receptors. In the clinical trials to support efficacy, BELSOMRA was superior to placebo for sleep latency and sleep maintenance as assessed both objectively by polysomnography and subjectively by patient-estimated sleep latency. The recommended dose of BELSOMRA is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. The total dose should not exceed 20 mg once daily.

Look for Shares of Merck to Potentially Pullback after Yesterday's 1.44% Rise
Comtex SmarTrend(R) - Wed Aug 13, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.16 to a high of $57.89. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.14 on volume of 10.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Watch for Merck to Potentially Pullback After Gaining 1.44% Yesterday
Comtex SmarTrend(R) - Wed Aug 13, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.16 to a high of $57.89. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.14 on volume of 10.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

FDA approves new sleeping drug from Merck
By MATTHEW PERRONE - AP - Wed Aug 13, 3:39PM CDT
WASHINGTON (AP) — Merck & Co. Inc. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep.

Dow Today: Merck (MRK) Higher
at The Street - Wed Aug 13, 1:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 70-cent gain (+1.2%) bringing the stock to $57.73.

Western Blotting (Instruments (Manual/Semi-automated/Automated) Market - Global Forecast to 2018
M2 - Wed Aug 13, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6nsxqt/western_blotting) has announced the addition of the "Western Blotting Market by Product, Consumables, by Application - End-User Analysis & Global Forecast to 2018" report to their offering. Western blotting is one of the most commonly used confirmatory tests for diagnosing diseases. This technique is extensively used in many pharmaceutical and biotechnology industries, academic research institutes, and diagnostic laboratories. This technique comprises a number of manual error-prone steps, hence companies are launching automated instruments. Thus, the instruments are increasingly being adopted by researchers as they not only simplify the work and give accurate results but also save considerable time. Automation in the western blotting workstations, global increase in life science R&D spending, growing proteomics market, rising prevalence of HIV, and companies focusing on validating the antibodies are the key factors that are expected to drive the growth of this market. However, high costs of primary antibodies and the emergence of alternative technologies restrain the growth of this market. The global western blotting market is categorized into four broad segments, namely, products, applications, end users, and geographies. On the basis of products, the market comprises instruments and consumables. Instruments are further sub-segmented by type into manual, semi-automated, and automated. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Western Blotting Market, By Product 5 Global Western Blotting Market, By Application 6 Global Western Blotting Market, By End User 7 Global Western Blotting Market, By Geography 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Advansta Inc. - Assay Horizons, Inc. - Bio-Rad Laboratories, Inc. - GE Healthcare - Li-Cor Biosciences - Merck Millipore - Perkinelmer, Inc. - Proteinsimple, Inc. - Roche Applied Science - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/6n...n_blotting




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 181

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 100

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 48

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Review Lawsuit Against Cepton, Inc. (CPTN)

Updated Category News Views 203

Class Action Against Cepton, Inc. Unveiled Recent developments have raised significant concerns for investors of Cepton, Inc. (NASDAQ: CPTN) following revelations of a class action lawsuit. Leading national plaintiffs' law firm Berger Montague has stepped in to help those impacted. The lawsuit focuses on investors who bought or sold Cepton shares during a specified...

Continue Reading
Exploring Uber Technologies: A Strategic Trade Perspective

Updated Category News Views 172

Uber Technologies Inc.'s Current Market Position Recently, ride-sharing giant Uber Technologies, Inc. (NYSE: UBER) experienced a notable increase in its market value. This uplift followed an innovative announcement regarding the capability for riders to book an Avride robotaxi, showcasing the evolution of autonomous mobility solutions. In the past five trading days, UBER...

Continue Reading
Celebrating Diversity: Winners of the Art Limitless Contest

Updated Category News Views 168

Celebrating the Art Limitless Competition Winners In the heart of artistic innovation, BE OPEN has unveiled the winners of the Art Limitless competition, an initiative celebrating inclusivity and diversity in the arts. This remarkable program strives to empower artists with disabilities, showcasing their work while inspiring broader societal awareness. What is Art...

Continue Reading
Certuity Welcomes Constantine Hatzivassiliou as New Partner

Updated Category News Views 246

Certuity Welcomes Constantine Hatzivassiliou as New Partner Certuity, a leading multi-family office dedicated to serving high-net-worth individuals and families, is thrilled to announce the promotion of Managing Director Constantine Hatzivassiliou to Partner. This significant advancement not only reflects Hatzivassiliou's commitment to the firm but also the invaluable...

Continue Reading
Sila Realty Trust, Inc.'s Key Updates on Q3 2024 Earnings

Updated Category News Views 124

Sila Realty Trust, Inc. Announces Upcoming Q3 Earnings Release Sila Realty Trust, Inc. (NYSE: SILA) recently made an announcement regarding its anticipated financial results for the third quarter of 2024. The company will release these earnings on a Tuesday morning, just before the market opens. This timely communication reflects Sila's commitment to transparency and...

Continue Reading